| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Alzamend Neuro, Inc. (ALZN) has 3 insiders with recent SEC Form 4 filings, including 8 buys and 2 sells. ALZN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 25 | $30.25 | - | |
| Dir | 0 | - | - | |
| Dir | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2022 | Gustafson Mark | Director | Sell | 20,000 | $1.21 | $24,202.00 | -25.0% | -28.4% | -65.4% | |
| Mar 28, 2022 | McGrath Lynne Fahey | Director | Sell | 25,000 | $1.21 | $30,325.00 | -25.0% | -24.0% | -64.3% | |
| Mar 18, 2022 | Ault Milton C III | 10% Owner | Buy | 100,000 | $1.10 | $110,450.00 | New | -27.4% | -64.6% | |
| Feb 24, 2022 | Ault Milton C III | 10% Owner | Buy | 22,500 | $1.15 | $25,960.50 | +0.3% | -22.9% | -57.5% | |
| Jan 27, 2022 | Ault Milton C III | 10% Owner | Buy | 2,500 | $1.40 | $3,487.50 | - | -33.3% | -52.2% | |
| Jan 24, 2022 | Ault Milton C III | 10% Owner | Buy | 5,000 | $1.29 | $6,449.50 | - | -36.5% | -58.2% | |
| Jan 18, 2022 | Ault Milton C III | 10% Owner | Buy | 7,000 | $1.66 | $11,619.30 | +0.1% | -39.2% | -61.8% | |
| Jan 14, 2022 | Ault Milton C III | 10% Owner | Buy | 3,000 | $1.79 | $5,368.20 | - | -41.9% | -66.9% | |
| Jan 7, 2022 | Ault Milton C III | 10% Owner | Buy | 3,000 | $1.93 | $5,775.00 | - | -45.3% | -69.3% | |
| Jan 5, 2022 | Ault Milton C III | 10% Owner | Buy | 2,000 | $1.98 | $3,958.60 | - | -44.2% | -70.5% |